Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A clinical development paradigm for cancer vaccines and related biologics.
Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group. Hoos A, et al. Among authors: urba w. J Immunother. 2007 Jan;30(1):1-15. doi: 10.1097/01.cji.0000211341.88835.ae. J Immunother. 2007. PMID: 17198079 Free article. Review.
Adoptive immunotherapy.
Sznol M, Urba WJ. Sznol M, et al. Among authors: urba wj. Cancer Chemother Biol Response Modif. 1993;14:227-48. Cancer Chemother Biol Response Modif. 1993. PMID: 8312104 Review. No abstract available.
Adoptive cellular therapy.
Sznol M, Urba WJ. Sznol M, et al. Among authors: urba wj. Cancer Chemother Biol Response Modif. 1991;12:213-30. Cancer Chemother Biol Response Modif. 1991. PMID: 1931444 Review. No abstract available.
Adoptive cellular therapy.
Sznol M, Urba WJ. Sznol M, et al. Among authors: urba wj. Cancer Chemother Biol Response Modif. 1992;13:191-204. Cancer Chemother Biol Response Modif. 1992. PMID: 1389910 Review. No abstract available.
Adoptive immunotherapy.
Sznol M, Urba WJ. Sznol M, et al. Among authors: urba wj. Cancer Chemother Biol Response Modif. 1994;15:213-25. Cancer Chemother Biol Response Modif. 1994. PMID: 7779587 Review. No abstract available.
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. Among authors: urba wj. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.
Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL. Fenton RG, et al. Among authors: urba wj. J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74. doi: 10.1097/00002371-199609000-00006. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8941876 Clinical Trial.
263 results